Aisling Capital, founded in 2000 and based in New York, is a private equity firm focused on mid-market and growth-oriented investments in the life sciences, healthcare, and technology sectors across the United States and Western Europe. The firm aims to capitalize on the anticipated revolution in healthcare driven by biotechnology, which is expected to transform the diagnosis, prevention, and treatment of serious illnesses. With the completion of the human genome project, new insights into the causes of disease have emerged, fostering innovative therapeutic approaches.

Aisling Capital supports leading global healthcare companies in their efforts to develop and commercialize new therapeutics, addressing the growing demand for capital in this rapidly advancing field.